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Introduction  
Sodium-glucose cotransporter 2 (SGLT2) is a protein located in the brush border of epithelial 
cells in the proximal tubule, which reabsorbs 90% of filtered glucose. Sodium-glucose 
cotransporter 2 inhibitors are a new class of oral medications for the treatment of type 2 diabetes 
mellitus (T2DM), which reduce plasma glucose levels by inhibiting the reabsorption of glucose 
from the proximal tubular epithelium. Sodium-glucose cotransporter 2 inhibitors are generally 
well tolerated, but this class of antidiabetic medications could be associated with serious 
adverse events, including euglycaemic diabetic ketoacidosis (euDKA), lower limb amputation, 
bone fracture, acute kidney injury, serious urinary tract infection, and venous thromboembolism 
[1]. Euglycaemic diabetic ketoacidosis is defined as DKA seen at a blood glucose level of less 
than 250 mg/dL. There are multiple mechanisms to explain the pathogenesis of euDKA in 
patients taking SGLT2 inhibitors, including hyperglucagonaemia, insulinopaenia, and 
overproduction of ketone bodies. Here, we report a patient with new-onset T2DM due to 
pancreatic cancer, who presented to the emergency room with euDKA on empagliflozin 
treatment. Furthermore, we performed a review of the literature previously reported SGLT2 
inhibitor-associated euDKA. 
 Case presentation 
A 58-year-old man presented to the emergency room with a one-day history of excessive thirst, 
slurred speech, and fever on October 23, 2019. Blood pressure was 90/60 mmHg, pulse rate 
was 124 beats/min, and body temperature was 38°C. The patient had no history of alcohol. On 
physical examination, oral mucosa was dry and skin turgor was moderately decreased. The 
initial laboratory findings are presented in Table 1.  
Two weeks before the emergency admission the patient’s medical history included impaired 
glucose tolerance, and he had a history of coronary artery disease for 10 years. He was on 
metformin twice daily. The patient was last seen by an endocrinologist with recent-onset T2DM 
2 weeks before the emergency admission; haemoglobin A1c was 8.3%, and the level of C-
peptide was 3.6 ng/mL at that time. Empagliflozin 10 mg once daily was added on October 7, 
2019. The patient had been suffering from mild vague epigastric pain and 3 kg unintentional 
weight loss for the last six months. He was referred to a gastroenterology outpatient clinic. 
Magnetic resonance (MR) imaging of the abdomen was planned. Abdominal MR showed a 
solid mass 3.9 cm in diameter at uncinate process of the pancreas (Fig. 1). Biopsy of the 
pancreatic mass was consistent with poorly differentiated adenocarcinoma (Fig. 2). When the 
patient was seen at the oncology outpatient clinic for chemotherapy, he complained of excessive 
thirst, fever, and slurred speech. He had been taking empagliflozin for 14 days. The patient was 
diagnosed with euDKA. He was treated with IV insulin infusion, and IV hydration therapy. The 
C-reactive protein level was elevated. However, the chest X-ray was normal and there was no 
symptom of urinary tract infection, but the patient was treated with broad-spectrum antibiotics 
for a possible infection. Ketoacidosis resolved in 12 hours and a subcutaneous basal-bolus 
insulin regimen was initiated. 
Figure 1. Abdominal T1-weighted MR scan showing solid mass 3.9 cm in size at the uncinate 
process 
 
Figure 2. Poorly differentiated adenocarcinoma of the pancreas: cells have large pleomorphic 
nuclei 
 
 
Discussion 
The use of SGLT2 inhibitors is increasing, mostly driven by the results of cardiovascular 
outcome trials showing reductions in major adverse cardiovascular events, hospitalisation for 
heart failure, and progression of renal disease in people with T2DM [2]. Despite this positive 
news, concerns remain about some of the adverse effects of this group of drugs. Sodium-glucose 
cotransporter 2 inhibitors have recently been shown to induce euDKA. Risk factors for euDKA 
include latent autoimmune diabetes of adulthood (LADA), surgery, low carbohydrate diets, 
insulin withdrawal or dose reduction, chronic liver disease or heavy alcohol intake, and acute 
illness [3]. 
Our patient had negative anti-GAD and anti-ICA antibodies. We excluded LADA. Long-
standing T2DM patients are at high risk of developing euDKA during SGLT2 inhibitor 
treatment [4]. Our patient’s diabetes was new onset. This is the first case of empagliflozin-
induced euDKA presenting with new-onset T2DM as an early sign of pancreatic cancer. 
Diabetic ketoacidosis as a first presentation of PAC is a rarely reported clinical condition [5]. 
It must be kept in mind that pancreatic cancer might be the precipitating factor for DKA in 
T2DM. Pancreatic cancer may have precipitated DKA through the factors that it secretes, which 
cause insulin resistance, or through causing insulinopaenia. In our case C-peptide level was 
normal, so insulinopaenia may not be the aetiology. In addition, prolonged fasting for the many 
procedures such as radiological imaging, pancreas biopsy procedure, venous port 
catheterisation, and finally acute infection might have precipitated euDKA in our case. 
 
Conclusion 
In our patient, euDKA probably occurred due to empagliflozin. Empagliflozin had been started 
in the patient for its favourable cardiovascular effects. Our patient’s diabetes was new onset. A 
point worth emphasising is that new-onset diabetes might be an early sign of pancreatic cancer. 
Malignancy may have increased the risk of euDKA when using SGLT2 inhibitor therapy. In 
particular, pancreatic cancer might have been a precipitating factor. Prolonged fasting for many 
procedures and acute infection might be the other underlying precipitating factors in our case. 
This group of drugs should be stopped especially if patients are going through a procedure that 
requires prolonged fasting. This is often a neglected issue that may precipitate euDKA. 
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Table 1. Initial laboratory findings 
Parameter (normal) Initial 
Arterial PH (7.36–7.44) 7.07 
Serum bicarbonate (21–28 
mmol/L) 
2.7 
Serum ketone (< 0.6 
mmol/L) 
3.5 
Anion gap g (8–16 mmol/L) 29 
Urine ketone (negative) +++ 
Serum lactate (0.5–1.4 
mmol/L) 
1.4 
Serum glucose (70–100 
mg/dL) 
206 
Glycosuria (< 50 mg/dL) 2000 
Serum sodium (135–145 
mEq/L) 
129 
Serum potassium (3.5–5.0 
mmol/L) 
3.9 
Chloride (98–107 mmol/L) 98.4 
Serum creatinine (0.8–1.2 
mg/dL) 
1.0 
Alanine transaminase (ALT) 
(< 35 U/L) 
10 
Aspartate transaminase 
(AST) (< 35 U/L) 
12 
Calcium (8.5–10.5 mg/dL) 9.6 
C-reactive protein (CRP) (< 
5 mg/L) 
237 
Procalcitonin (< 0.5 ng/mL) 36.4 
Leucocytes (4.1–11.1 Ku/L) 17.33 
 
 
